ArticleVaccines2021
Antibodies Responses to SARS-CoV-2 in a Large Cohort of Vaccinated Subjects and Seropositive Patients.
Article in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Emergence of SARS-CoV-2 Omicron lineages shifted antibody-mediated protection curves.iScience · 2025Article
- Humoral immune response following the third dose of BNT162b2 received by employees at a Slovak cancer healthcare facility.Biomedical reports · 2025Article
- Employment of a high throughput functional assay to define the critical factors that influence vaccine induced cross-variant neutralizing antibodies for SARS-CoV-2.Scientific reports · 2023Article
- Article
- Use of Self-Collected Dried Blood Spots and a Multiplex Microsphere Immunoassay to Measure IgG Antibody Response to COVID-19 Vaccines.Microbiology spectrum · 2023Article
- Impaired immunity and high attack rates caused by SARS-CoV-2 variants among vaccinated long-term care facility residents.Immunity, inflammation and disease · 2022Article
- The durability of natural infection and vaccine-induced immunity against future infection by SARS-CoV-2.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Neutralizing Antibodies Response against SARS-CoV-2 Variants of Concern Elicited by Prior Infection or mRNA BNT162b2 Vaccination.Vaccines · 2022Article
- Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines.Nature medicine · 2022Article
- Neutralizing antibodies to SARS-CoV-2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects.European journal of immunology · 2022Article
- Article
- Waning Humoral Response after COVID-19 mRNA Vaccination in Maintenance Dialysis Patients and Recovery after a Complementary Third Dose.Vaccines · 2022Article
- Article
- Methodology to estimate natural- and vaccine-induced antibodies to SARS-CoV-2 in a large geographic region.PloS one · 2022Article
- Serological Response to SARS-CoV-2 Messenger RNA Vaccine: Real-World Evidence from Italian Adult Population.Vaccines · 2021Article
- Physicians' Experience with COVID-19 Vaccination: A Survey Study.Healthcare (Basel, Switzerland) · 2021Article
- COVID-19 serological evaluation in a cohort of Vaccinated and Seropositive healthcare workers.Acta bio-medica : Atenei Parmensis · 2021Article
- Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers.Vaccines · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 is a current global threat, and the characterization of antibody response is vitally important to update vaccine development and strategies. In this study we assessed SARS-CoV-2 antibody concentrations in SARS-CoV-2 positive patients (N = 272) and subjects vaccinated with the BNT162b2 m-RNA COVID-19 vaccine (N = 1256). For each participant, socio-demographic data, COVID-19 vaccination records, serological analyses, and SARS-CoV-2 infection status were collected. IgG antibodies against S1/S2 antigens of SARS-CoV-2 were detected. Almost all vaccinated subjects (99.8%) showed a seropositivity to anti-SARS-COV-2 IgG and more than 80% of vaccinated subjects had IgG concentrations > 200 AU/mL. In a Tobit multivariable regression analysis, SARS-CoV-2 vaccination was statistically significantly associated with increased IgG concentrations (β coef = 266.4;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.